Cardiac AI: The Billion Dollar ROI Imperative for Investors

Cardiovascular disease is the costliest diagnostic category in healthcare, period. It’s a massive financial hole for health systems. So when you’re trying to sell AI into this space, there’s really only one thing that matters: measurable, system-level economic ROI. It’s the gatekeeper for getting a hospital to buy your product and for keeping investors from walking away. There’s plenty of excitement about AI in healthcare, but our executive surveys tell the same story every quarter, the C-suite isn’t wowed by cool tech, they want to see real financial returns.

The Shifting Sands of AI Healthcare Investment: From Administrative Efficiency to Clinical ROI

The way people think about AI investment in healthcare has definitely changed. A few years ago, the first wave of money chased administrative efficiencies, tools that promised to make operations simpler and cut overhead. The problem was, for most of these tools, proving a real, significant ROI was a nightmare. Our quarterly “Proprietary Executive Survey” with health system CFOs and CIOs confirms this. When they’re looking at any AI that requires a big check or a painful integration, they’re now laser-focused on one question: does this have a direct clinical impact that I can see on my balance sheet as a cost reduction or new revenue? You can see this play out perfectly by looking at the difference between companies like Tempus AI and Viz.ai, who are succeeding with clinical value, and the spectacular flameout of Olive AI. Olive was the poster child for healthcare AI investment, raising around $900 million from big names like Tiger Global, but it completely collapsed. Why? Our analysis of their capital loss shows it was because they could never consistently prove a measurable ROI that made their high costs worthwhile. Hospital execs were interested in the idea of automating admin work, but when it came time to renew contracts, they couldn’t point to a single dollar saved that was directly because of Olive’s platform. So they walked. It proves a simple point: ROI isn’t some fuzzy concept. It has to be a range of outcomes you can actually point to, with clear, attributable financial benefits tied to them.

Quantifying Cardiovascular ROI: The Tempus AI and Viz.ai Approaches

Where Olive AI went wrong with its admin focus, companies like Tempus AI and Viz.ai are getting it right by targeting clinical applications, especially in the high-cost world of cardiovascular care. Tempus AI, with its eye-watering $12.8 billion valuation (as of Aug 2026) and backing from GV, made its name in precision oncology. Now they’re making a calculated move into cardiology with the same playbook: use AI to personalize treatment and improve outcomes, which in turn drives down long-term costs. We don’t have direct, peer-reviewed cardiovascular ROI figures from Tempus just yet, but their approach of combining genomic and clinical data to make diagnostics and therapies more precise is exactly what’s needed to stop wasting money on ineffective treatments for complex heart conditions. Investors are especially interested in the massive “data moat” Explanation of data moats in AI they’re building, which is a huge competitive advantage that also makes their models better. Viz.ai is probably the best current example of a company delivering hard, measurable ROI in the cardiovascular space. After a $100 million Series D that valued it at $1.2 billion (its implied valuation is now closer to $443 million as of Aug 2026), with Tiger Global also an investor, the company has proven its model works. Its AI platform for coordinating stroke care has shown it can reduce time-to-treatment and give patients better outcomes. And while the product is for acute stroke, the basic idea of using AI to speed up critical care applies to all kinds of cardiovascular problems. When we talk to executives in our survey, they keep bringing up Viz.ai’s ability to show them the numbers, reduced length of stay, better patient disposition, smoother care coordination. These are the kinds of hard cost-reduction metrics that get a CFO’s attention. Plus, the fact that they have multiple 510(k) clearances and De Novo approvals for their SaMD FDA guidance on Software as a Medical Device (SaMD) takes a lot of the risk off the table for both hospitals and investors.

The Investor Imperative: Prioritizing Verifiable Clinical Impact

The message for investors and VCs couldn’t be clearer: back the healthcare AI startups that can show you clear, contractually-backed clinical ROI. You have to be able to demonstrate it. The time for funding vague promises of “efficiency gains” without any hard numbers to back them up is over. The market will crush companies that can’t connect their tech to real economic results for the health system. Our “Proprietary Executive Survey” data shows that hospital execs are all looking for the same things in an AI solution:

• Directly reduce costs: Things like lower readmission rates, shorter hospital stays, fewer unnecessary procedures, and catching diagnostic errors. The benchmark here is something like Hello Heart’s peer-reviewed study, which showed their platform cut $1,709 in annual healthcare costs and inpatient days by 47% Hello Heart peer-reviewed study on cardiovascular cost savings.
• Improve patient outcomes: When outcomes get better, you see higher patient satisfaction, less risk of getting sued, and a better reputation, all of which have real, if indirect, financial upside.
• Integrate smoothly: A solution that doesn’t cause a massive headache for existing workflows and actually works with other systems is always going to be preferred.
• Possess clear regulatory pathways: If a company has 510(k) clearance or a De Novo classification for its SaMD, it’s a good signal they’re serious about safety and efficacy, which de-risks the whole deal. A solid QMS and being ISO 13485 certified ISO 13485 standard for medical devices is also just basic table stakes for due diligence. The spectacular failure of Olive AI is the perfect lesson here. All the funding and vision in the world don’t matter if you can’t deliver measurable value to the health system paying the bills. This is why we see so many “zombie companies” in health AI, they get some seed money, maybe even an FDA clearance, but they can’t close the big enterprise deals because they have no proof of ROI.
  

  Methodology Note: Synthesizing Executive Insight and Venture Performance

So how did we arrive at this analysis? We combined two things: our proprietary survey responses from over 200 health system executives (CFOs, CIOs, CMOs) across North America, and a deep dive into venture capital performance data. Our “Quantitative Impact Analysis” approach isn’t complicated, we just listen to what the actual buyers are saying they need and use that as our framework for judging the real-world economic impact of AI. By comparing the purchasing criteria from our executive surveys with the financial performance and investment history of companies like Tempus AI, Viz.ai, and the failed Olive AI, we can give investors a much clearer picture of what actually leads to success or failure in the AI healthcare market, especially for cardiovascular ROI. In the end, what’s going to decide the future of AI in high-cost fields like cardiology isn’t the tech itself, but whether companies can turn their products into verifiable, system-level economic wins. The investors who get this will be the ones who make money on the next wave of health AI companies. It’s really that simple.